期刊
JOURNAL OF RADIOANALYTICAL AND NUCLEAR CHEMISTRY
卷 330, 期 1, 页码 1-13出版社
SPRINGER
DOI: 10.1007/s10967-021-07922-6
关键词
Immuno-PET; Molecular imaging; Radiopharmaceuticals; Zr-89; Cancer
This review discusses the potential of molecular imaging agents labeled with Zr-89 radionuclide for cancer tissue imaging, with a focus on nanoparticles showing greater potential than antibodies for radiopharmaceutical development.
The development of molecular imaging agents used for imaging of cancer tissue is of great importance for the early detection of cancer. Positron emission tomography (PET) radiopharmaceuticals consists of a positron-emitting radionuclide and a molecularstructure. Zr-89-labeled monoclonal antibodies (mAbs), peptides, nanoparticles, proteins, and other compounds are called Zr-89-Immuno-PET and are used in cancer tissue imaging. This review provides a general overview of the potential of molecules labeled with Zr-89 radionuclide, which is chosen due to its long half-life, in preclinical and clinical studies. In light of these studies, radiopharmaceuticals created using nanoparticles have greater potential than those using antibodies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据